RxDoctor Payments Data

Todd Wien, MD

Family Medicine · Plano, TXNPI 1265440275

Payments from drug & device makers

$9,459in general payments, 2019–2025

Across 576 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • GSK$812
  • Lilly USA, LLC$651
  • Johnson & Johnson$419
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$9,447100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,459 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$168,436
Medicare patients
467
Services billed
2,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$192,816
TrulicityDulaglutide68$96,828
Humira(Cf) PenAdalimumab12$83,496
JardianceEmpagliflozin55$67,567
MounjaroTirzepatide63$65,931
FarxigaDapagliflozin Propanediol57$54,322
XareltoRivaroxaban27$38,875
EliquisApixaban24$23,398
MyrbetriqMirabegron12$10,645
ProzacFluoxetine Hcl12$9,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,325
Tresiba Flextouch U-200Insulin Degludec13$8,765
JanumetSitagliptin Phos/Metformin Hcl12$6,309
SymbicortBudesonide/Formoterol Fumarate16$5,502
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,013$192,816139 claims
Lilly USA, LLCTrulicity, Mounjaro$651$162,758131 claims
Boehringer IngelheimJardiance$372$67,56755 claims
AstraZenecaFarxiga, Symbicort$1,516$59,82473 claims
Johnson & JohnsonXarelto$419$38,87527 claims
PfizerEliquis$234$23,39824 claims
GSKTrelegy Ellipta, Anoro Ellipta$812$14,64526 claims
Astellas Pharma US IncMyrbetriq$68$10,64512 claims
MerckJanumet$274$6,30912 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$91$3,641393 claims
AbbVieSynthroid$1,054$3,05461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →